Alterations in hla class i‐presented immunopeptidome and class i‐interactome upon osimertinib resistance in egfr mutant lung adenocarcinoma

Abstract

Immune checkpoint inhibitor (ICI) therapy has been a paradigm shift in the treatment of cancer. ICI therapy results in durable responses and survival benefit for a large number of tumor types. Osimertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase in-hibitor (TKI) has shown great efficacy treating EGFR mutant lung cancers; however, all patients eventually develop resistance. ICI therapy has not benefitted EGFR mutant lung cancer. Herein, we employed stable isotope labeling by amino acids in cell culture (SILAC) quantitative mass spec-trometry‐based proteomics to investigate potential immune escape molecular mechanisms in osi-mertinib resistant EGFR mutant lung adenocarcinoma by interrogating the alterations in the human leukocyte antigen (HLA) Class I‐presented immunopeptidome, Class I‐interactome, and the whole cell proteome between isogenic osimertinib‐sensitive and ‐resistant human lung adenocarcinoma cells. Our study demonstrates an overall reduction in HLA class I‐presented immunopeptidome and downregulation of antigen presentation core complex (e.g., TAP1 and ERAP1/2) and immuno-proteasome in osimertinib resistant lung adenocarcinoma cells. Several key components in autoph-agy pathway are differentially altered. S100 proteins and SLC3A2 may play critical roles in reduced antigen presentation. Our dataset also includes ~1000 novel HLA class I interaction partners and hundreds of Class I‐presented immunopeptides in EGFR mutant lung adenocarcinoma. This large-scale unbiased proteomics study provides novel insights and potential mechanisms of immune evasion of EGFR mutant lung adenocarcinoma.